TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2874780

Group type: EXPERIMENTAL
Intervention: Ketazolam once daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Divided doses of ketazolam (from earlier study)
Number of subjects: 14
Study: 29170944

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS targeting the insular cortex
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS targeting the insular cortex
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 8
Study: 27919356

Group type: EXPERIMENTAL
Intervention: niacin monotherapy (N = 118)
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin monotherapy (n = 155)
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (10/20 mg) + niacin (to 2 g) (N = 279)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 552
Study: 24102228

Group type: EXPERIMENTAL
Intervention: Supervised ICD patient group
Number of subjects: 327
Study: 24172024

Group type: EXPERIMENTAL
Intervention: Classroom-based cognitive-behavioural therapy (CBT)
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Attention control PSHE
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Usual PSHE
Number of subjects: 1064
Study: 19357009

Group type: EXPERIMENTAL
Intervention: Revolving-door flap (RD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Full-thickness skin graft (FTSG)
Number of subjects: 40
Study: 18422535

Group type: EXPERIMENTAL
Intervention: Support groups
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 15800981

Group type: EXPERIMENTAL
Intervention: LAM monotherapy (group A)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Initial interferon plus LAM treatment followed by LAM monotherapy (group B)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: b2m elevation duration in responders (group A)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: b2m levels decrease at 3 months (group A)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: b2m status at baseline (group A)
Number of subjects: 37
Study: 12356387

Group type: EXPERIMENTAL
Intervention: Cerivastatin 400 microg plus regular margarine 25 g
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cerivastatin 400 microg plus sterol‐ester margarine 25 g
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Placebo plus sterol‐ester margarine 25 g (2 g of plant sterol)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo plus regular margarine 25 g
Number of subjects: 152
Study: 10334346

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.5% ophthalmic suspension
Number of subjects: 245

Group type: COMPARATOR
Intervention: Prednisolone acetate 1.0% ophthalmic suspension
Number of subjects: 245
Study: 8567330

Group type: EXPERIMENTAL
Intervention: HFX RT with 1.2 Gy twice daily, total dose of 64.8 Gy in 27 treatment days, shorter interfraction interval (4.5-5 h)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: HFX RT with concurrent chemotherapy (carboplatin and etoposide) every week, shorter interfraction interval (4.5-5 h)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: HFX RT with concurrent chemotherapy (carboplatin and etoposide) every other week, shorter interfraction interval (4.5-5 h)
Number of subjects: 169

Group type: COMPARATOR
Intervention: HFX RT with 1.2 Gy twice daily, total dose of 64.8 Gy in 27 treatment days, longer interfraction interval (5.5-6 h)
Number of subjects: 169

Group type: COMPARATOR
Intervention: HFX RT with concurrent chemotherapy (carboplatin and etoposide) every week, longer interfraction interval (5.5-6 h)
Number of subjects: 169

Group type: COMPARATOR
Intervention: HFX RT with concurrent chemotherapy (carboplatin and etoposide) every other week, longer interfraction interval (5.5-6 h)
Number of subjects: 169
Study: 1760051

Group type: EXPERIMENTAL
Intervention: Alcohol users
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 7036032

Group type: EXPERIMENTAL
Intervention: Methylene blue dye
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Carbon-14-labeled urea
Number of subjects: 63

Group type: COMPARATOR
Intervention: Calcium-45
Number of subjects: 63

Group type: COMPARATOR
Intervention: Iodine-125-labeled albumin
Number of subjects: 63
Study: 29624749

Group type: EXPERIMENTAL
Intervention: Sleep-deprived group (N=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Well-rested group (N=50)
Number of subjects: 100
Study: 28111908

Group type: EXPERIMENTAL
Intervention: α-tocopherol acetate oil and silicone–vitamin E gauzes (group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: α-tocopherol acetate oil and traditional moist gauzes (group 1)
Number of subjects: 60
Study: 25339518

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily during the open-label maintenance (OLM) study
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo during the randomized controlled trial (RCT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg twice daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 82
Study: 23827131

Group type: EXPERIMENTAL
Intervention: Low-fat diet with high omega-3 fatty acids (LFn3; 23% energy as fat)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fat diet (LF; 20% energy as fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-fat diet (40% energy as fat)
Number of subjects: 0
Study: 21929645

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 44
Study: 19922613

Group type: EXPERIMENTAL
Intervention: SHED-IT intervention (Internet-based weight-loss program)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Information only control group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: SHED-IT intervention
Number of subjects: 65
Study: 18073548

Group type: EXPERIMENTAL
Intervention: 1 mg/kg propofol at the end of surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 80
Study: 15855580

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg for 3 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 16
Study: 12219661

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 10558391

Group type: EXPERIMENTAL
Intervention: Smoking intervention program, specific details not provided.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group derived from participants' compliance to program instructions.
Number of subjects: 0
Study: 7604145

Group type: EXPERIMENTAL
Intervention: 400 mg BAHS before sleep for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2356213

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg) at 6 hours postmorphine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg) at 24 hours postmorphine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg) at 6 and 24 hours postmorphine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg) at 24 hours postmorphine preceded by naloxone at 6 hours
Number of subjects: 6
Study: 42333

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (8 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination of chlorpheniramine and cimetidine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31151425

Group type: EXPERIMENTAL
Intervention: Nutritional counseling, nutritional supplements (rich in branched-chain amino acids), and a home-based exercise program (low-intensity daily muscle training and lifestyle education).
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Nutritional counseling, nutritional supplements, and exercise program (as above).
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 130
Study: 28556061

Group type: EXPERIMENTAL
Intervention: 100 mg ASA intravenously
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 mg enteric-coated ASA bid
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 81 mg chewable ASA
Number of subjects: 30
Study: 26033265

Group type: EXPERIMENTAL
Intervention: Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin (TP)
Number of subjects: 67
Study: 23878192

Group type: EXPERIMENTAL
Intervention: Xylazine (1.1 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detomidine (20 mug/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medetomidine (5 mug/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (3.5 mug/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Romifidine (100 mug/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 21851879

Group type: EXPERIMENTAL
Intervention: β‐blockade
Number of subjects: 8988

Group type: COMPARATOR
Intervention: β‐blockade (U.S. cohort)
Number of subjects: 8988

Group type: COMPARATOR
Intervention: β‐blockade (ROW cohort)
Number of subjects: 8988
Study: 19623203

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.5 g/day, 1.5 g/day total n-3 PUFA)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo (high oleic sunflower oil)
Number of subjects: 77
Study: 17444382

Group type: EXPERIMENTAL
Intervention: Standard treatment combined with cycloidal vibration therapy (Vibro‐Pulse), 30 minutes per treatment, three times per day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard treatment (intravenous or oral antibiotic therapy) and bed rest
Number of subjects: 36
Study: 16529174

Group type: EXPERIMENTAL
Intervention: Superoxide anion production measured by cytochrome c reduction
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Anti-ox-LDL autoantibody titres in gingival blood
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 8-OHdG concentration in venous blood
Number of subjects: 56

Group type: COMPARATOR
Intervention: 8-OHdG levels in gingival blood
Number of subjects: 56

Group type: COMPARATOR
Intervention: Total antioxidant status (TAS) in venous blood serum
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 8-OHdG concentration in gingival blood
Number of subjects: 56
Study: 11718589

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroid (fluticasone propionate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral antihistamine (loratadine)
Number of subjects: 0
Study: 9151795

Group type: EXPERIMENTAL
Intervention: cM‐T412 (chimeric CD4 monoclonal antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8197566

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (group A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion with rh‐EPO (group A1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Homologous blood transfusion (group B)
Number of subjects: 42
Study: 3069539

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.30 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pentazocine 30 mg
Number of subjects: 20
Study: 31982581

Group type: EXPERIMENTAL
Intervention: 2 mg, 5 mg, or 10 mg PedPRM nightly up to 104 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (2-week withdrawal period)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PedPRM (2, 5, or 10 mg nightly)
Number of subjects: 80
Study: 30310225

Group type: EXPERIMENTAL
Intervention: ENGAGE intervention delivered during routine dental check-ups to 335 patients by 18 GDPs.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Patient survey regarding lifestyle questions asked by dentists.
Number of subjects: 1000
Study: 28320223

Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg/day
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg/day
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 26275761

Group type: EXPERIMENTAL
Intervention: Parent-coached exposure therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Traditional CBT (pre-exposure anxiety management strategies)
Number of subjects: 14
Study: 23114849

Group type: EXPERIMENTAL
Intervention: LGG plus smectite (3 g)
Number of subjects: 88

Group type: COMPARATOR
Intervention: LGG alone (placebo)
Number of subjects: 88
Study: 21420788

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen and tropisetron
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16
Study: 18822830

Group type: EXPERIMENTAL
Intervention: Stimulant medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonstimulant medications
Number of subjects: 0
Study: 16642613

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding therapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Fluoxetine (medication group)
Number of subjects: 88
Study: 14579046

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated NIRx stent
Number of subjects: 20
Study: 11094887

Group type: EXPERIMENTAL
Intervention: Low‐intensity infrared laser radiation to the tympanic vessels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local transcutaneous laser radiation of the affected joints
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transcutaneous laser radiation
Number of subjects: 0
Study: 8669653

Group type: EXPERIMENTAL
Intervention: General anaesthesia with air (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anaesthesia with nitrous oxide (Group N)
Number of subjects: 30
Study: 1569443

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Carboplatin 300 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 342
Study: 2857276

Group type: EXPERIMENTAL
Intervention: Triangular moulded rubber mask ('Rendell‐Baker')
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Circular silicone rubber mask ('Laerdal')
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cleaning with 70% ethanol
Number of subjects: 44
Study: 29991122

Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation together with 10 sessions of WBMF therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional rehabilitation (control group)
Number of subjects: 73
Study: 27145328

Group type: EXPERIMENTAL
Intervention: Behaviour change techniques (BCTs) based on the health action process approach plus a views-on-ageing component
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Behaviour change techniques (BCTs) with an additional planning task
Number of subjects: 310

Group type: COMPARATOR
Intervention: Behaviour change techniques (BCTs) targeting volunteering
Number of subjects: 310

Group type: COMPARATOR
Intervention: No intervention (passive control group)
Number of subjects: 310
Study: 24016360

Group type: EXPERIMENTAL
Intervention: Small-sided games
Number of subjects: 25

Group type: COMPARATOR
Intervention: Change-of-direction training
Number of subjects: 25
Study: 22904565

Group type: EXPERIMENTAL
Intervention: AMI cell infusion (n = 57)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: OMI cell infusion (n = 22)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group for AMI (n = 60)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group for OMI (n = 24)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Cell infusion group (n = 79)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (n = 84)
Number of subjects: 163
Study: 20515510

Group type: EXPERIMENTAL
Intervention: Workplace-oriented intervention for burnout
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (declined participation)
Number of subjects: 74
Study: 18658019

Group type: EXPERIMENTAL
Intervention: On-field alternative warm-up program, performed 3 times per week during the fall 2002 season
Number of subjects: 1435

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1435
Study: 15928071

Group type: EXPERIMENTAL
Intervention: Paclitaxel at 175 mg/m2 plus Carboplatin at 7 AUC (Arm A)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Paclitaxel at 175 mg/m2 plus alternating Carboplatin at 7 AUC and Cisplatin at 75 mg/m2 (Arm B)
Number of subjects: 247
Study: 14562186

Group type: EXPERIMENTAL
Intervention: Duruöz's Hand Index (DHI)
Number of subjects: 60
Study: 10906292

Group type: EXPERIMENTAL
Intervention: Cryopreserved arteries (20% dimethylsulphoxide, stored for an average of 22 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fresh-control arteries (tested for 24 hours after harvesting)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cryopreserved veins
Number of subjects: 120

Group type: COMPARATOR
Intervention: Unfrozen veins (control)
Number of subjects: 120
Study: 8826549

Group type: EXPERIMENTAL
Intervention: 0.2 mL NaCl 0.9%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.5 mL NaCl 0.9%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.0 mL NaCl 0.9%
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1.5 mL NaCl 0.9%
Number of subjects: 18
Study: 1598734

Group type: EXPERIMENTAL
Intervention: Thiphenamil 400 mg q.i.d.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 6589660

Group type: EXPERIMENTAL
Intervention: Desmethylimipramine (DMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desmethylimipramine (DMI) withdrawal
Number of subjects: 0
Study: 30711959

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 5099

Group type: COMPARATOR
Intervention: No trastuzumab
Number of subjects: 5099
Study: 30260246

Group type: EXPERIMENTAL
Intervention: New information sheet (minimising reference to falls)
Number of subjects: 4145

Group type: COMPARATOR
Intervention: Standard information sheet
Number of subjects: 4145
Study: 26566149

Group type: EXPERIMENTAL
Intervention: Trimethoprim, 200 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 24769557

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy using the Amadeo Robotic System
Number of subjects: 20

Group type: COMPARATOR
Intervention: Occupational therapy executed by a trained physiotherapist
Number of subjects: 20
Study: 21904839

Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS)
Number of subjects: 36
Study: 21144969

Group type: EXPERIMENTAL
Intervention: Management guided by individualized NT-proBNP target
Number of subjects: 345

Group type: COMPARATOR
Intervention: Clinically-guided outpatient management
Number of subjects: 345
Study: 17432677

Group type: EXPERIMENTAL
Intervention: Modified Daotan Decoction (DD) + risperidone 3.16 +/- 0.73 mg/d
Number of subjects: 65

Group type: COMPARATOR
Intervention: Risperidone 5.11 +/- 1.27 mg/d
Number of subjects: 65
Study: 11124171

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercial enzymatic stain remover
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 9066933

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ticlopidine 250 mg
Number of subjects: 18
Study: 8378946

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Warfarin (INR 2.0 to 4.5)
Number of subjects: 24
Study: 2947148

Group type: EXPERIMENTAL
Intervention: Trimetazidine 60 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29180306

Group type: EXPERIMENTAL
Intervention: GnRH analogue
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (nonpharmacologic treatment)
Number of subjects: 99
Study: 25720763

Group type: EXPERIMENTAL
Intervention: Intensive diabetes management initiated within 1 week of diagnosis
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 67
Study: 25539671

Group type: EXPERIMENTAL
Intervention: Video-based intervention to improve skin self-examination (SSE) behaviour
Number of subjects: 831

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 831
Study: 22588635

Group type: EXPERIMENTAL
Intervention: whey hydrolysate (hydro-meal)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: whey isolate (iso-meal)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lac-meal
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CGMP-meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: whey protein fractions
Number of subjects: 12
Study: 20297744

Group type: EXPERIMENTAL
Intervention: Education with alcohol-based hand sanitizer
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Education with hand sanitizer and face masks
Number of subjects: 509

Group type: COMPARATOR
Intervention: Education
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Hand Sanitizer
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Mask wearing
Number of subjects: 509
Study: 18790556

Group type: EXPERIMENTAL
Intervention: Anatomical form crown
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Flat occlusal table with occlusal contacts
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Flat occlusal table without occlusal contacts
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All types of crowns
Number of subjects: 19
Study: 15689764

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with adrenaline (1:200,000)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Saline with adrenaline (1:200,000)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Saline without adrenaline
Number of subjects: 76
Study: 14559892

Group type: EXPERIMENTAL
Intervention: Preoperative AC followed by docetaxel
Number of subjects: 2411

Group type: COMPARATOR
Intervention: Preoperative AC alone
Number of subjects: 2411
Study: 10648489

Group type: EXPERIMENTAL
Intervention: Tedisamil 50 mg twice daily
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Tedisamil 100 mg twice daily
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Tedisamil 150 mg twice daily
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203